ZZZhaohui Sunny Zhou

Zhaohui Sunny Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhaohui Sunny Zhou has a total of 127 co-authors. Here are the top co-authors by number of shared publications:

  • Amissi Sadiki

    Northeastern University Department of Chemistry and Chemical Biology Boston, MA 02115

    6 shared publications
  • Shujia Dai

    Barnett Institute of Chemical and Biological Analysis, Northeastern University, Boston Massachusetts 02115, United States

    4 shared publications
  • Tianzhu Zang

    Barnett Institute of Chemical and Biological Analysis, Department of Chemistry and Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States

    4 shared publications
  • Wenqin Ni

    Barnett Institute of Chemical and Biological Analysis, Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115

    4 shared publications
  • Barry L. Karger

    Barnett Institute of Chemical and Biological Analysis and Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115

    3 shared publications
  • Da Ren

    Process and Product Development, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320, United States

    3 shared publications

Latest Publications

  • Activatable photoimmunotherapy enables spatiotemporal depletion of pathogenic cells in immune-driven disease and cancer

    by Eric M. Kercher, Amissi Sadiki, Shanshan Liu, Kingsley I. Essien, John Scudiere, William J.J. Finlay, Andrea H. Epperly, Zhaohui Sunny Zhou, Bryan Q. Spring, John E. Harris

  • Open Access

    Elucidation of Proteoforms of Chinese Hamster Ovary (CHO) Phospholipase B‐Like 2 (PLBL2) Captured From a Monoclonal Antibody

    by Michael E. Dolan, Lei (Leo) Wang, Alexander Tedeschi, Yan Wang, Christopher Barton, Sheldon F. Oppenheim, Zhaohui Sunny Zhou

    Removing host cell proteins (HCPs) during biotherapeutic manufacturing is essential to ensure patient safety and supply continuity. Yet, this goal remains exceptionally challenging for some HCP species. For example, phospholipase B‐like‐2 (PLBL2) from Chinese hamster ovary (CHO) cells plagues process engineers by evading typical purification strategies. Separation challenges for CHO PLBL2 and other HCPs are due in large part to a dearth of detailed biochemical characterization for HCPs, such as their proteoforms or variants. Herein, we present as a case study the elucidation of proteoforms of PLBL2, which was endogenously expressed in CHO alongside pembrolizumab (a monoclonal IgG4 antibody) and inadvertently co‐purified following a typical downstream process. Using site‐specifically modified polyclonal anti‐CHO PLBL2 antibodies immobilized onto a solid support, CHO PLBL2 was captured from pembrolizumab, enriched, and recovered, enabling deep characterization by mass spectrometry and other techniques. These analyses revealed a detailed understanding of CHO PLBL2's proteoforms, including charge variants, N‐linked and O‐linked glycosylation, phosphorylation, and cleavage to afford multiple molecular weight isoforms. To the best of our knowledge, this is the first published, deep characterization of a challenging CHO HCP. Armed with a greater understanding of the impurities that plague purification processes, we can design new, targeted strategies to ensure their removal and safeguard both patient safety and biotherapeutic supplies. While our work centered on CHO PLBL2, our antibody immobilization, affinity enrichment, and characterization approach should be broadly applicable to enable the examination of innumerable challenging HCPs from modalities across the increasingly diverse bioprocessing landscape.


  • Open Access

    Bi-functional integrin degraders cause stronger anti-proliferative effects than a blocking antibody by modulating distinct downstream signaling

    by Meghan F. Monroy, Megan Krumpoch, T. Andrew McTeague, Angela Fee, Dooyoung Lee, Zhaohui Sunny Zhou, Fu-Yang Lin

    Integrins play a critical role in signaling events that regulate cell adhesion, migration, and proliferation, processes that, when dysregulated, contribute to cancer progression. Recently, innovative approaches that target extracellular proteins for degradation have suggested potential in cancer treatment by removing specific cell surface receptors and trafficking them to the lysosome for breakdown. In this context, two integrin degraders were engineered, each exploiting different lysosomal targeting pathways: the asialoglycoprotein receptor (ASGPR) and zinc and ring finger 3 (ZNRF3), respectively. Both degraders use a pan-selective human αv antibody that fully blocks ligand binding, effectively internalizing and degrading αv integrins in vitro and in vivo. Degrading cell-surface αv integrins, rather than merely blocking their interactions with the extracellular matrix (ECM), produces a stronger anti-proliferative effect by more robustly modulating oncogenic signaling pathways. Notably, these degraders exploit distinct mechanisms, including the first reporting of more profound changes in tumor-promoting integrin signaling cascades compared to ligand blocking alone, highlighting a novel avenue for integrin-targeted drug development. This strategy leads to greater suppression of tumor cell growth making it a promising and potentially superior approach to cancer therapy. Similar to other reports, in vivo efficacy has yet to be shown with extracellular or membrane-targeted protein degraders. Through careful pharmacokinetics characterizations, we showed that lack of in vivo efficacy may be due to insufficient exposure and target engagement. Our study provides useful lessons for the field to fully realize the full potential for the next generation of degrader therapeutics.


  • Open Access

    First site-specific conjugation method for native goat IgG antibodies via glycan remodeling at the conserved Fc region

    by Michael E Dolan, Amissi Sadiki, Leo (Lei) Wang, Yan Wang, Christopher Barton, Sheldon F Oppenheim, Zhaohui Sunny Zhou

    Despite their triumph in treating human diseases, antibody therapies for animals have gained momentum more slowly. However, the first approvals of animal antibodies for osteoarthritic pain in cats and dogs may herald the dawn of a new era. For example, goats are vital to economies around the world for their milk, meat, and hide products. It is therefore imperative to develop therapies to safeguard goats—with antibodies at the forefront. Goat antibodies will be crucial in the development of therapeutic antibodies, for example, as tracers to study antibody distribution in vivo, reagents to develop other therapeutic antibodies, and therapeutic agents themselves (e.g., antibody-drug conjugates). Hamstringing this effort is a still-burgeoning understanding of goat antibodies and their derivatization. Historically, goat antibody conjugates were generated through stochastic chemical modifications, producing numerous attachment sites and modification ratios, thereby deleteriously impacting antigen binding. Site-specific methods exist but often require substantial engineering and have not been demonstrated with goat antibodies. Nevertheless, we present herein a novel method to site-specifically conjugate native goat antibodies: chemo-enzymatic remodeling of the native Fc N-glycan introduces a reactive azide handle, after which click chemistry with strained alkyne partners affords homogeneous conjugates labeled only on the Fc domain. This process is robust, and resulting conjugates retain their antigen binding and specificity. To our knowledge, our report is the first for site-specific conjugation of native goat antibodies. Furthermore, our approach should be applicable to other animal antibodies—even with limited structural information—with similar success.


  • Open Access

    Site-Specific Conjugation of Native Antibody: Transglutaminase-Mediated Modification of a Conserved Glutamine While Maintaining the Primary Sequence and Core Fc Glycan via Trimming with an Endoglycosidase

    by Amissi Sadiki, Shanshan Liu, Shefali R. Vaidya, Eric M. Kercher, Ryan T. Lang, James McIsaac, Bryan Q. Spring, Jared R. Auclair, Zhaohui Sunny Zhou

    A versatile chemo-enzymatic tool to site-specifically modify native (nonengineered) antibodies is using transglutaminase (TGase, E.C. 2.3.2.13). With various amines as cosubstrates, this enzyme converts the unsubstituted side chain amide of glutamine (Gln or Q) in peptides and proteins into substituted amides (i.e., conjugates). A pleasant surprise is that only a single conserved glutamine (Gln295) in the Fc region of IgG is modified by microbial TGase (mTGase, EC 2.3.2.13), thereby providing a highly specific and generally applicable conjugation method. However, prior to the transamidation (access to the glutamine residue by mTGase), the steric hindrance from the nearby conserved N-glycan (Asn297 in IgG1) must be reduced. In previous approaches, amidase (PNGase F, EC 3.5.1.52) was used to completely remove the N-glycan. However, PNGase F also converts a net neutral asparagine (Asn297) to a negatively charged aspartic acid (Asp297). This charge alteration may markedly change the structure, function, and immunogenicity of an IgG antibody. In contrast, in our new method presented herein, the N-glycan is trimmed by an endoglycosidase (EndoS2, EC 3.2.1.96), hence retaining both the core N-acetylglucosamine (GlcNAc) moiety and the neutral asparaginyl amide. The trimmed glycan also reduces or abolishes Fc receptor-mediated functions, which results in better imaging agents by decreasing nonspecific binding to other cells (e.g., immune cells). Moreover, the remaining core glycan allows further derivatization such as glycan remodeling and dual conjugation. Practical and robust, our method generates conjugates in near quantitative yields, and both enzymes are commercially available.


  • Open Access

    The emergence of AntibodyPlus: the future trend of antibody-based therapeutics

    by Yong Zhu, Shawn Shouye Wang, Zhaohui Sunny Zhou, Mitchell Ho

    To date, close to 100 canonical monoclonal antibody drugs have been approved by the FDA; furthermore, a number of antibody-derived therapeutics in nontraditional formats have reached late development stages and the market, and many more are being evaluated in early-stage development. To better reflect this trend and to set up a framework for forward thinking, we herein introduce the concept of AntibodyPlus, embracing any therapeutics with an antibody component. AntibodyPlus therapeutics contain effector modules, in the form of small molecules, nucleic acids, proteins or even cells, to enhance their therapeutic activities against cancer, virus infection and other diseases. In this short review, we discuss historic perspective and current status of therapeutic antibody development, and the scope and categories of AntibodyPlus therapeutics along with their advantages, applications and challenges. We also present several examples that highlight their design principles, potentials and future trends.


  • Open Access

    A Mass Spectrometric Characterization of Light-Induced Modifications in Therapeutic Proteins

    by Zhongqi Zhang, Sih-Yao Chow, Ronandro De Guzman, Nathan H. Joh, Marisa K. Joubert, Jason Richardson, Bhavana Shah, Mats Wikström, Zhaohui Sunny Zhou, Jette Wypych


  • Open Access

    Site-specific conjugation of native antibody

    by Amissi Sadiki, Shefali R Vaidya, Mina Abdollahi, Gunjan Bhardwaj, Michael E Dolan, Harpreet Turna, Varnika Arora, Athul Sanjeev, Timothy D Robinson, Andrea Koid, et al.

    Traditionally, non-specific chemical conjugations, such as acylation of amines on lysine or alkylation of thiols on cysteines, are widely used; however, they have several shortcomings. First, the lack of site-specificity results in heterogeneous products and irreproducible processes. Second, potential modifications near the complementarity-determining region may reduce binding affinity and specificity. Conversely, site-specific methods produce well-defined and more homogenous antibody conjugates, ensuring developability and clinical applications. Moreover, several recent side-by-side comparisons of site-specific and stochastic methods have demonstrated that site-specific approaches are more likely to achieve their desired properties and functions, such as increased plasma stability, less variability in dose-dependent studies (particularly at low concentrations), enhanced binding efficiency, as well as increased tumor uptake. Herein, we review several standard and practical site-specific bioconjugation methods for native antibodies, i.e., those without recombinant engineering. First, chemo-enzymatic techniques, namely transglutaminase (TGase)-mediated transamidation of a conserved glutamine residue and glycan remodeling of a conserved asparagine N-glycan (GlyCLICK), both in the Fc region. Second, chemical approaches such as selective reduction of disulfides (ThioBridge) and N-terminal amine modifications. Furthermore, we list site-specific antibody–drug conjugates in clinical trials along with the future perspectives of these site-specific methods.


  • Site‐specific Bioconjugation and Convergent Click Chemistry Enhances Antibody–Chromophore Conjugate Binding Efficiency

    by Amissi Sadiki, Eric M. Kercher, Haibin Lu, Ryan T. Lang, Bryan Q. Spring, Zhaohui Sunny Zhou

    Photosensitizer (PS)–antibody conjugates (photoimmunoconjugates, PICs) enable cancer cell‐targeted photodynamic therapy (PDT). Nonspecific chemical bioconjugation is widely used to synthesize PICs but gives rise to several shortcomings. The conjugates are heterogeneous, and the process is not easily reproducible. Moreover, modifications at or near the binding sites alter both binding affinity and specificity. To overcome these limitations, we introduce convergent assembly of PICs via a chemo‐enzymatic site‐specific approach. First, an antibody is conjugated to a clickable handle via site‐specific modification of glutamine (Gln) residues catalyzed by transglutaminase (TGase, EC 2.3.2.13). Second, the modified antibody intermediate is conjugated to a compatible chromophore via click chemistry. Utilizing cetuximab, we compared this site‐specific conjugation protocol to the nonspecific chemical acylation of amines using N‐hydroxysuccinimide (NHS) chemistry. Both the heavy and light chains were modified via the chemical route, whereas, only a glutamine 295 in the heavy chain was modified via chemo‐enzymatic conjugation. Furthermore, a 2.3‐fold increase in the number of bound antibodies per cell was observed for the site‐specific compared with nonspecific method, suggesting that multiple stochastic sites of modification perturb the antibody–antigen binding. Altogether, site‐specific bioconjugation leads to homogenous, reproducible and well‐defined PICs, conferring higher binding efficiency and probability of clinical success.


  • Site-Specific Reversible Protein and Peptide Modification: Transglutaminase-Catalyzed Glutamine Conjugation and Bioorthogonal Light-Mediated Removal

    by Kevin R. Moulton, Amissi Sadiki, Bilyana N. Koleva, Lincoln J. Ombelets, Tina H. Tran, Shanshan Liu, Bryan Wang, Hongyan Chen, Emily Micheloni, Penny J. Beuning, et al.

    Dynamic photoswitches in proteins that impart spatial and temporal control are important to manipulate and study biotic and abiotic processes. Nonetheless, approaches to install these switches into proteins site-specifically are limited. Herein we describe a novel site-specific method to generate photo-removable protein conjugates. Amine-containing chromophores (e.g., venerable o-nitrobenzyl and less-explored o-nitrophenylethyl groups) were incorporated via transamidation into glutamine side-chain of alpha-gliadin, LCMV and TAT peptides, as well as beta-casein and UmuD proteins by transglutaminase (TGase, EC 2.3.2.13). Subsequently, photolysis regenerated the native peptides and proteins. When this modification leads to the reduction or abolishment of certain activities, the process is referred to as caging, as in the case for E. coli polymerase manager protein UmuD. Importantly, this method is simple, robust and easily adaptable, e.g., all components are commercially available.